Étiquette : phytocannabinoïdes

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain, Esraa Aly et al.,

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106   Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]

Lire la suite

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice, Eva M. Schleicher et al., 2019

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094   The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]

Lire la suite

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products, Qingfang Meng et al., 2018

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products Qingfang Meng, Beth Buchanan, Jonathan Zuccolo, Mathieu-Marc Poulin, Joseph Gabriele, David Charles Baranowski PLoS ONE, 2018, 13, (5), e0196396. https://doi.org/10.1371/journal.pone.0196396   Abstract In the past 50 years, Cannabis sativa (C. sativa) has gone from a substance essentially prohibited worldwide to one that is gaining acceptance both culturally and legally in many countries for medicinal and recreational use. As additional jurisdictions legalize Cannabis products and the variety and complexity of these products surpass the classical dried plant material, appropriate methods for measuring the biologically active constituents is paramount to ensure [...]

Lire la suite

Isolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol, Pasquale Linciano et al., 2019

Isolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol Pasquale Linciano, Cinzia Citti, Livio Luongo, Carmela Belardo, Sabatino Maione, Maria Angela Vandelli, Flavio Forni, Giuseppe Gigli, Aldo Laganà, Carmela Maria Montone, Giuseppe Cannazza Journal of Natural Products, 2019 Dec 31. doi: 10.1021/acs.jnatprod.9b00876.   Abstract The butyl homologues of Δ9-tetrahydrocannabinol, Δ9-tetrahydrocannabutol (Δ9-THCB), and cannabidiol, cannabidibutol (CBDB), were isolated from a medicinal Cannabis sativa variety (FM2) inflorescence. Appropriate spectroscopic and spectrometric characterization, including NMR, UV, IR, ECD, and HRMS, was carried out on both cannabinoids. The chemical structures and absolute configurations of the isolated cannabinoids were [...]

Lire la suite

Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial, Aleksandra Nitecka-Buchta et al., 2019

Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial Aleksandra Nitecka-Buchta, Anna Nowak-Wachol, KacperWachol, KarolinaWalczynska-Dragon, Paweł Olczyk, Olgierd Batoryna, Wojciech Kempa and Stefan Baron Journal of Clinical Medicine, 2019, 8, 188, 1-17. doi : 10.3390/jcm8111886 Abstract Background : The healing properties of cannabidiol (CBD) have been known for centuries. In this study, we aimed to evaluate the efficiency of the myorelaxant effect of CBD after the transdermal application in patients with myofascial pain. Methods : The Polish version of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD Ia and Ib) was used. A total of 60 patients were enrolled [...]

Lire la suite

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation, Roger Hudson et al., 2019

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette The Journal of Neuroscience, 2019 https://doi.org/10.1523/JNEUROSCI.0708-19.2019   Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in-vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency and bursting rates, decreases GABA frequency, and [...]

Lire la suite

Cannabis Oil : chemical evaluation of an upcoming cannabis-based medicine, Luigi L. Romano, Arno Hazekamp, 2013

Cannabis Oil : chemical evaluation of an upcoming cannabis-based medicine Luigi L. Romano, Arno Hazekamp Cannabinoids, 2013, 1, (1), 1-11 © International Association for Cannabinoid Medicines   Abstract Concentrated cannabis extracts, also known as Cannabis oils because of their sticky and viscous appearance, are becoming increasingly popular among self-medicating patients as a claimed cure for cancer. In general, preparation methods for Cannabis oils are relatively simple and do not re-quire particular instruments. The most well-known example of such a product is called ‘Simpson oil’. The purpose of the extraction, often followed by a solvent evaporation step, is to make canna-binoids and other beneficial components such as [...]

Lire la suite

The Role of Cannabis within an Emerging Perspective on Schizophrenia, Jegason P. Diviant et al., 2018

The Role of Cannabis within an Emerging Perspective on Schizophrenia Jegason P. Diviant, Jacob M. Vigil, and Sarah S. Stith Medicines, 2018, 5, 86, 1-11. doi : 10.3390/medicines5030086   Abstract Background : Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods : We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results : A review of the literature shows that phytocannabinoid consumption may [...]

Lire la suite

Cannabidiol as a potential treatment for psychosis, Cathy Davies and Sagnik Bhattacharyya, 2019

Cannabidiol as a potential treatment for psychosis Cathy Davies and Sagnik Bhattacharyya Therapeutic Advances in Psychopharmacology, 2019, Vol. 9, 1–16 https://doi.org/10.1177%2F2045125319881916   Abstract : Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of [...]

Lire la suite